Omeros Corporation shares jumped premarket after the US Food and Drug Administration approved Yartemlea (narsoplimab-wuug), the first treatment for TA-TMA. The drug is cleared for adults and children aged two and older, with a US launch planned for January 2026, fuelling bullish retail sentiment.